Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP... see more

TSXV:HEM - Post Discussion

Hemostemix Inc > $HEM ACP-01 clinical trial scores
View:
Post by robert345 on Jun 16, 2022 11:01am

$HEM ACP-01 clinical trial scores

$HEM has already announced the results from its 2nd phase CLI trial under the guidance of Hemostemix itself, which has noted healing of ulcers and resolution of the pain of ischemia, which occurred in more than 80% of patients.
Comment by WalterTheDawg on Jun 16, 2022 1:13pm
You spammers should probably stick to snippets of NRs and stay away from distorting the truth. That was an interim result from 12 patients and without unblinding we don't even know if all the patients that did well had acp or placebo
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities